ライフサイエンスコーパス: nosocomial infection

1 tobacter baumannii is a significant cause of nosocomial infection.

2 s associated with an increased risk for VLBW nosocomial infection.

3 hazard for women of childbearing age or as a nosocomial infection.

4 novel avenues for therapy and prevention of nosocomial infection.

5 C5a-mediated dysfunction and acquisition of nosocomial infection.

6 ogen Clostridium difficile, a major cause of nosocomial infection.

7 ated pneumonia (VAP) is a common and serious nosocomial infection.

8 t hosts, but they are also leading causes of nosocomial infection.

9 en, prominent in antimicrobial-resistant and nosocomial infection.

10 ave shown mixed results in the prevention of nosocomial infection.

11 mechanisms used by E. faecalis to establish nosocomial infection.

12 nit length of stay >48 hrs were followed for nosocomial infection.

13 of packed red blood cells is associated with nosocomial infection.

14 n, immunosuppression, and the development of nosocomial infection.

15 coccus faecium (VREfm) is a leading cause of nosocomial infection.

16 r developing fecal carriage that may lead to nosocomial infection.

17 ated with levels of the type 2 cytokines and nosocomial infection.

18 e L. pneumophila population as the source of nosocomial infection.

19 hylococcus aureus (MRSA) is a major cause of nosocomial infection.

20 rial biofilms responsible for persistent and nosocomial infections.

21 sociated with an increased susceptibility to nosocomial infections.

22 e a modifiable risk factor for postoperative nosocomial infections.

23 y related species are commonly implicated in nosocomial infections.

24 ticular, is now one of the leading causes of nosocomial infections.

25 which is responsible for the development of nosocomial infections.

26 n immune function can predispose patients to nosocomial infections.

27 humans, and is one of the leading causes of nosocomial infections.

28 an opportunistic pathogen that causes severe nosocomial infections.

29 medical environment and causes severe human nosocomial infections.

30 of the predominant bacterium encountered in nosocomial infections.

31 nantly in (sub)species that frequently cause nosocomial infections.

32 c concern for food safety, bioterrorism, and nosocomial infections.

33 terococcus faecium (VRE) is a major cause of nosocomial infections.

34 become one of the most prevalent and costly nosocomial infections.

35 associated with increased risk of death and nosocomial infections.

36 ounds, which is one of the causes of serious nosocomial infections.

37 ally ill patients are at heightened risk for nosocomial infections.

38 inetobacter baumannii causes a wide range of nosocomial infections.

39 ment of tuberculosis, HIV, and perinatal and nosocomial infections.

40 nts may respond to lung injury and postnatal nosocomial infections.

41 eus is an important cause of mortality among nosocomial infections.

42 cystic fibrosis (CF), and a leading cause of nosocomial infections.

43 as recently emerged as an important cause of nosocomial infections.

44 d to the emergence of E. faecium and CC17 in nosocomial infections.

45 toward reductions in ICU length of stay and nosocomial infections.

46 both responses to lung injury and postnatal nosocomial infections.

47 soil and water and are an important cause of nosocomial infections.

48 MRSA) has created challenges in treatment of nosocomial infections.

49 ic pathogens and among the leading causes of nosocomial infections.

50 e of the most commonly isolated organisms in nosocomial infections.

51 nd from patients with food-borne disease and nosocomial infections.

52 nd associated means to control P. aeruginosa nosocomial infections.

53 c fibrosis patients and is a major source of nosocomial infections.

54 a, especially during food-borne outbreaks or nosocomial infections.

55 DUWL biofilm may have beneficial effects on nosocomial infections.

56 h, sexually transmitted infections and major nosocomial infections.

57 ding causes of bacteraemia and other serious nosocomial infections.

58 aureus is a common pathogen associated with nosocomial infections.

59 most frequently associated with outbreaks of nosocomial infections.

60 as been associated with an increased risk of nosocomial infections.

61 ections at surgical sites and prevents other nosocomial infections.

62 opportunistic pathogens and major causes of nosocomial infections.

63 ity of pathogens to evolve in the context of nosocomial infections.

64 ida species are one of the leading causes of nosocomial infections.

65 ticularly high-risk population to intestinal nosocomial infections.

66 s responsible for approximately one-third of nosocomial infections.

67 ere associated with subsequent occurrence of nosocomial infections.

68 dysfunction responsible for poor outcome and nosocomial infections.

69 cost-effective mechanism to monitor emerging nosocomial infections.

70 testinal tract (GIT) and an agent of serious nosocomial infections.

71 ndependently associated with higher risk for nosocomial infections.

72 a L. pneumophila population responsible for nosocomial infections.

73 ingly been recognized as a major pathogen in nosocomial infections.

74 evices, it has emerged as a leading cause of nosocomial infections.

75 h, sexually transmitted infections and major nosocomial infections.

76 ve bacterium responsible for a wide range of nosocomial infections.

77 responsible for up to 10% of gram-negative, nosocomial infections.

78 56 inpatients, 63% were classified as having nosocomial infections.

79 A) which is one of the most common causes of nosocomial infections.

80 shock and correlated to adverse outcomes or nosocomial infections.

81 ic fibrosis patients and is a major agent of nosocomial infections.

82 ents were used to estimate the proportion of nosocomial infections.

83 V infections were more heterogeneous than in nosocomial infections.

84 ulitis are projected to cause more than 9000 nosocomial infections, 1000 to 5000 Clostridium difficil

85 ated ventilator-associated complication were nosocomial infections (27.3% and 43.8%), including venti

86 ted infection (29% versus 16%; P = 0.019) or nosocomial infection (37% versus 16%; P < 0.001) than in

87 empirical antibiotic therapy was very low in nosocomial infections (40%), compared to HCA and CA epis

88 = .49), mortality (16.3% and 9.8%, p = .38), nosocomial infections (43% vs. 57%, p = .16), and acute

89 h health care-associated infection (52%) and nosocomial infection (61%) but was uncommon in the group

90 55 years, 52% hepatitis C virus [HCV], 15.8% nosocomial infection, 96% Child score >/= 7) and 30-day

91 esponsible for large numbers of postsurgical nosocomial infections across the United States and world

92 er on mortality, multiple organ failure, and nosocomial infection, after controlling for all importan

93 ng human pathogen and a significant cause of nosocomial infections among hospital patients worldwide.

94 We then compared incidence of nosocomial infections among infants in these two groups

95 These are associated with higher rates of nosocomial infections among infants with very low birth

96 Invasive candidiasis (IC) is the most common nosocomial infection and a leading cause of mycoses-rela

97 organ failure is associated with subsequent nosocomial infection and increased mortality.

98 g phases II and III, the association between nosocomial infection and individual phase was not signif

99 ificantly greater in patients that developed nosocomial infection and organ dysfunction than similarl

100 about the pathophysiology of post-traumatic nosocomial infection and organ failure, findings have be

101 njury is common, but is often complicated by nosocomial infection and organ failure.

102 The associations between nosocomial infection and patient age, sex, and NoV genot

103 eumoniae, which are frequently implicated in nosocomial infection and preterm infant gut colonization

104 tridioides difficile is the leading cause of nosocomial infections and a worldwide urgent public heal

105 tant strains of this bacterium cause serious nosocomial infections and are the leading cause of death

106 unsaturated fatty acids on the prevalence of nosocomial infections and clinical outcomes in medical a

107 Enterococci account for nearly 10% of all nosocomial infections and constitute a significant treat

108 common opportunistic pathogen implicated in nosocomial infections and in chronic lung infections in

109 yunsaturated fatty acids reduces the risk of nosocomial infections and increases the predicted time f

110 ient transfers, contributes to the spread of nosocomial infections and investigate how network struct

111 Enterococcus faecalis is a leading cause of nosocomial infections and is known for its ability to ac

112 an important opportunistic pathogen causing nosocomial infections and is often associated with infec

113 and M. abscessus, have been associated with nosocomial infections and occupational hypersensitivity

114 Furthermore, complications like nosocomial infections and organ failure are not associat

115 ad to better informed decision making around nosocomial infections and other time-dependent exposures

116 Acinetobacter baumannii frequently causes nosocomial infections and outbreaks.

117 1 are associated with a higher incidence of nosocomial infections and seem to be major actors of sep

118 intervention to help reduce the incidence of nosocomial infections and sepsis postburn.

119 blood transfusions had a higher incidence of nosocomial infections and sepsis, and the amount of bloo

120 These organisms are a major concern in nosocomial infections and should therefore be monitored

121 nfections (UTIs) are the most common type of nosocomial infection, and Candida albicans is the most f

122 shock, while the onset of the effect of age, nosocomial infection, and cirrhosis was later.

123 cted by a nationally based system monitoring nosocomial infection, and described in a prospectively a

124 result in higher rates of organ dysfunction, nosocomial infection, and length of hospital stay.

125 to their antibiotic resistance, incidence of nosocomial infection, and person-to-person transmission.

126 HRS were age, high baseline serum bilirubin, nosocomial infection, and reduction in serum creatinine

127 lower risk-adjusted rate of 7-day mortality, nosocomial infection, and severe intraventricular hemorr

128 blood cells was related to the occurrence of nosocomial infection, and there was a dose-response patt

129 frequency of shock reversal, acquisition of nosocomial infections, and changes in body temperature,

130 ient and family verbal abuse, patient falls, nosocomial infections, and medications errors.

131 ciation between red blood cell transfusions, nosocomial infections, and poorer outcomes in critically

132 Pseudomonas aeruginosa is a leading cause of nosocomial infections, and resistance to virtually all a

133 common source of health care-associated and nosocomial infections, and Staphylococcus aureus was the

134 the immaturity of their immune systems, and nosocomial infections are a significant risk factor for

135 Nosocomial infections are responsible for significant mo

136 Nosocomial infections are those that become evident 48 h

137 Many nosocomial infections arise from gastrointestinal coloni

138 ted readmissions consistently had index-stay nosocomial infections as a predictor for HE, renal/metab

139 aureus nasal carriage and increased risk of nosocomial infection, as well as increased carriage due

140 rected for survival probability, the risk of nosocomial infection associated with red blood cell tran

141 n-resistant enterococci are a major cause of nosocomial infections but are rarely found in humans in

142 lator-associated pneumonia (VAP) is a common nosocomial infection causing significant morbidity and m

143 iated with cirrhosis severity, diabetes, and nosocomial infections; close monitoring of patients with

144 Nosocomial infections continue to be important causes of

145 The implementation the International Nosocomial Infection Control Consortium multidimensional

146 The International Nosocomial Infection Control Consortium ventilator-assoc

147 s to analyze the effect of the International Nosocomial Infection Control Consortium's multidimension

148 etwork, and the methodology of International Nosocomial Infection Control Consortium.

149 A synergistic combination of available nosocomial infection control strategies could prevent ne

150 s aureus (MRSA) is fundamental to modern-day nosocomial infection control, both for epidemiologic inv

151 hospital admission, discharge criteria, and nosocomial infection control.

152 ts with advanced cirrhosis and prevention of nosocomial infections could reduce this burden.

153 thors present a method for analyzing typical nosocomial infection data consisting of results from arb

154 The analysis of nosocomial infection data for communicable pathogens is

155 ssions during each phase, point estimates of nosocomial infections decreased by 22% during phase II a

156 en-day, 28-day, and hospital stay mortality; nosocomial infection, defined as an infection in blood o

157 have emerged as a cause of endocarditis and nosocomial infections despite being normal commensals of

158 ys (interquartile range, 2-11 d) and 21% had nosocomial infections diagnosed after status epilepticus

159 However, surprisingly, nosocomial infection did not increase subsequent multipl

160 covering from inpatient vascular surgery and nosocomial infections did not occur.

161 nterobacter, genera commonly associated with nosocomial infections, dominate the preterm infant gut m

162 The incidence of nosocomial infections due to carbapenem-resistant Klebsi

163 logy, risk factors, and impact on outcome of nosocomial infections during extracorporeal membrane oxy

164 est KP activity, both at baseline, developed nosocomial infections during follow-up.

165 taxa containing species that commonly cause nosocomial infections (e.g., Enterobacteriaceae) that we

166 [95% confidence interval {CI}, .30-.83]) and nosocomial infection empirically treated with imipenem o

167 bacterial species that are common sources of nosocomial infections, Escherichia coli and Staphylococc

168 d pharmaceutical industries to help minimize nosocomial infection, food spoilage, and pharmaceutical

169 atistically significant increase in rates of nosocomial infection for transfused patients regardless

170 rtunistic Gram-negative pathogen that causes nosocomial infections for which there are limited treatm

171 nosocomial transmission; 24% of patients had nosocomial infections from an unknown source; and 43% we

172 nd those developing symptoms later as having nosocomial infection has a positive predictive value and

173 ients out of the hospital, and thereby avoid nosocomial infections, has created an ever-growing need

174 -associated pneumonia, as well as with other nosocomial infections, has created an imperative to redu

175 excess length of stay (LOS) attributable to nosocomial infections have failed to address time-varyin

176 ity of illness, degree of organ dysfunction, nosocomial infection, hospital mortality, and other pote

177 ssociated pneumonia (VAP) is the most common nosocomial infection in critically ill patients.

178 m difficile infection is a relatively common nosocomial infection in mechanically ventilated patients

179 ha production) and an increased risk of late nosocomial infection in some patients.

180 B. animalis subsp. lactis failed to prevent nosocomial infections in an acute-setting pediatric hosp

181 The incidence of nosocomial infections in children in developed countries

182 ns are needed for the empirical treatment of nosocomial infections in cirrhosis.

183 inosa is frequently a causative organism for nosocomial infections in critically ill patients and is

184 stridium difficile causes one of the leading nosocomial infections in developed countries, and therap

185 occus faecalis is frequently responsible for nosocomial infections in humans and represents one of th

186 of the incidence and microbiology of various nosocomial infections in patients with cancer-a large, i

187 nflower seed oil provides protection against nosocomial infections in preterm very low birthweight in

188 ciated bloodstream infections are similar to nosocomial infections in terms of frequency of various c

189 cterium animalis subsp. lactis in preventing nosocomial infections in the acute hospital setting.

190 coccus epidermidis are the leading causes of nosocomial infections in the United States and often are

191 enhance skin barrier function would prevent nosocomial infections in this population.

192 importation and transmission influence MRSA nosocomial infections in Veterans Affairs Medical Center

193 the association between RBC transfusion and nosocomial infection; in all these studies blood transfu

194 Fungi cause serious nosocomial infections including candidiasis and aspergil

195 s is a major cause of community-acquired and nosocomial infections including the life-threatening con

196 tors underlying the outcome of P. aeruginosa nosocomial infections, including aspects related to the

197 stant opportunist causing difficult-to-treat nosocomial infections, including endocarditis, but there

198 Enterococcus faecalis is a leading agent of nosocomial infections, including urinary tract infection

199 r of neonatal patients at risk for acquiring nosocomial infections is increasing because of the impro

200 Enterococcus faecium is a leading source of nosocomial infections, it appears to lack many of the ov

201 rding Acinetobacter isolates responsible for nosocomial infections, little is known about these organ

202 ference was found for the duration of common nosocomial infections [mean (range): 3.58 (1-7) vs. 3.79

203 dent predictors for development of ACLF were nosocomial infections, Model for Endstage Liver Disease

204 Nosocomial infections, mortality rates, and intensive ca

205 Effective strategies to prevent nosocomial infection must include continuous monitoring

206 tality, incidence of complications including nosocomial infection, neurologic decompensation (stroke)

207 that renders trauma patients susceptible to nosocomial infections (NI) and prolonged intensive care

208 ce and impact on adult patients' outcomes of nosocomial infections (NIs) occurring during venoarteria

209 ces and transmission routes in patients with nosocomial infections not linked to other patients and a

210 tings worldwide empirical therapy in serious nosocomial infections now requires the use of carbapenem

211 osuppression and increased susceptibility to nosocomial infections observed in critically ill sepsis

212 lthcare settings, yet the greatest burden of nosocomial infection occurs in resource-restricted setti

213 0.05) and was associated independently with nosocomial infection (odds ratio (OR), 5.5, 95% confiden

214 ansfusions was independently associated with nosocomial infection (odds ratio 1.097; 95% confidence i

215 Nosocomial infection of health-care workers (HCWs) durin

216 Nosocomial infections of Elizabethkingia species can hav

217 sitive bacterium that can cause a variety of nosocomial infections of which urinary tract infections

218 Enterococcus faecium is a common cause of nosocomial infections, of which infective endocarditis i

219 [95% CI, 1.07-1.32], P = .001); presence of nosocomial infection (OR = 36.3 [95% CI, 9.71-135.96], P

220 also was associated with the development of nosocomial infections (OR, 3.2; 95% CI, 1.7-5.5; p < .01

221 Nosocomial infection, organ failure, and mortality in th

222 icroflora that has become a leading cause of nosocomial infections over the past several decades.

223 interval 1.96-53.32), and the development of nosocomial infections (p < 0.05, Mann-Whitney U test).

224 cells transfused, the greater the chance of nosocomial infection; p< 0.0001 chi-square).

225 ginosa is among the leading causes of severe nosocomial infections, particularly affecting critically

226 Pseudomonas aeruginosa is a major cause of nosocomial infections, particularly in immunocompromised

227 nt-line antibiotic used for the treatment of nosocomial infections, particularly those caused by meth

228 Nosocomial infections pose a significant threat to patie

229 is the fourth most common cause of systemic nosocomial infections, posing a significant risk in immu

230 sed percentages of blood MDSCs had increased nosocomial infections, prolonged intensive care unit sta

231 Leukoreduction tended to reduce the nosocomial infection rate but not significantly.

232 The nosocomial infection rate for the entire cohort was 5.94

233 The posttransfusion nosocomial infection rate was 14.3% in 428 evaluable pat

234 A subgroup analysis of nosocomial infection rates adjusted for probability of s

235 erall mortality, multiple organ failure, and nosocomial infection rates for the entire cohort (n = 1,

236 The nosocomial infection rates for the transfusion group (n

237 ervention phase, hand hygiene compliance and nosocomial infection rates improved suggesting that ongo

238 We determined the nosocomial infection rates in these groups while adjusti

239 female gender on multiple organ failure and nosocomial infection rates remains significant in both p

240 Nosocomial infection rates were compared among three gro

241 rtality Prediction Model scores, have higher nosocomial infection rates, longer intensive care unit a

242 terial coatings on medical devices to reduce nosocomial infection rates.

243 important cause of community-associated and nosocomial infections related to exposure to aqueous env

244 rong predictor for subsequent acquisition of nosocomial infection (relative risk, 5.8; 95% confidence

245 CI, 0.68-1.90; I = 51.6%) and acquisition of nosocomial infections (relative risk, 1.13; 95% CI, 0.61

246 occurs and the relevance for acquisition of nosocomial infection remain undetermined.

247 te measure of importation, transmission, and nosocomial infection, respectively.

248 23% lower risk of multiple organ failure and nosocomial infection, respectively.

249 Many nosocomial infections result from the ability of microor

250 colistin (COS) are emerging causes of severe nosocomial infections, reviving interest in the use of c

251 Although the overall rate of nosocomial infections significantly decreased when combi

252 rging pathogen that causes a wide variety of nosocomial infections, spreads rapidly within hospitals,

253 " pathogen which is a major cause of serious nosocomial infections such as bacteremia, sepsis, and en

254 Furthermore, nosocomial infections such as invasive aspergillosis and

255 ptococcus pneumoniae is a causative agent of nosocomial infections such as pneumonia, meningitis, and

256 onsible for a wide range of life-threatening nosocomial infections, such as septicemia, peritonitis,

257 iscrimination was compared with the National Nosocomial Infection Surveillance (NNIS) risk index.

258 sed on definitions set forth by the National Nosocomial Infection Surveillance System.

259 ) by participating hospitals in the National Nosocomial Infections Surveillance (NNIS) System in the

260 wide surveillance components of the National Nosocomial Infections Surveillance System hospitals duri

261 through routine surveillance, using National Nosocomial Infections Surveillance system methodology.

262 d by definitions and methods of the National Nosocomial Infections Surveillance System.

263 according to the guidelines of the National Nosocomial Infections Surveillance System.

264 for Disease Control and Prevention National Nosocomial Infections Surveillance.

265 reduced Centers for Disease Control National Nosocomial Infection Survey VAP (14/19; 73.6%) to (5/14;

266 in the literature, predicted by the National Nosocomial Infection System, or described by our own ins

267 sunflower oil are less likely to experience nosocomial infections than are control infants.

268 wer seed oil were 41% less likely to develop nosocomial infections than controls (adjusted incidence

269 to prevent this infection, as well as other nosocomial infections that complicate the hospital cours

270 ostridium difficile is the cause of emerging nosocomial infections that result in abundant morbidity

271 diabetes have increased recurrent, chronic, nosocomial infections that worsen the long-term morbidit

272 though classically thought to be primarily a nosocomial infection, the incidence of community-acquire

273 ity of survival by using MPM-0 scores showed nosocomial infection to occur at consistently higher rat

274 ntibiotic therapy were more likely to have a nosocomial infection, to have underlying cancer or diabe

275 The rate of nosocomial infection was a secondary outcome.

276 Patients whose nosocomial infection was diagnosed before transfusion we

277 Nosocomial infection was mainly associated with older ag

278 The prevalence of nosocomial infections was detected during 28 days of ICU

279 n into account that the overall incidence of nosocomial infections was lower than expected.

280 The number of patients with nosocomial infections was significantly reduced in the f

281 ridium difficile colitis, a leading cause of nosocomial infection, was studied in humans and in a mur

282 faecalis important for its ability to cause nosocomial infections, we suggest that the one-component

283 ood cells transfused, the odds of developing nosocomial infection were increased by a factor of 1.5.

284 Nosocomial infections were defined as infections that oc

285 of </= 20 TIPS/year, variceal bleeding, and nosocomial infections were independent risk factors for

286 ved, and predicted an increased incidence of nosocomial infection, whereas persistence of multiple or

287 vironmental commensal and a leading cause of nosocomial infections, which are often caused by multire

288 Candida albicans is a common cause of nosocomial infections whose virulence depends on the rev

289 nisms, this review explores risk factors for nosocomial infection with methicillin-resistant Staphylo

290 o delayed referral versus risk of death from nosocomial infection with severe acute respiratory syndr

291 Nosocomial infections with Clostridium difficile are on

292 BACKGROUND & AIMS: Nosocomial infections with Clostridium difficile present

293 Nosocomial infections with Klebsiella pneumoniae are a f

294 sessing the comorbidity-attributable risk of nosocomial infections with methicillin-resistant Staphyl

295 Enterococci are the leading cause of nosocomial infections worldwide and acquired resistance

296 Staphylococcus aureus is a major cause of nosocomial infections worldwide, and the rate of resista

297 mannii has emerged as a significant cause of nosocomial infections worldwide, there have been few inv

298 nii is a Gram-negative bacterium that causes nosocomial infections worldwide, with recent prevalence

299 obacter baumannii is a significant source of nosocomial infections worldwide.

300 , known to cause both community-acquired and nosocomial infections worldwide.